title: [Antitumor effect of dioxadet in intraperitoneal chemoperfusion treatment for advanced ovarian cancer in experimental setting].
abstract: The study of antitumor efficacy of dioxadet in chemoperfusion treatment of ascitic ovarian cancer was carried out in 125 Wistar female rats. Ovarian cancer was inoculated intraperitoneally at a number 1x10(7) tumor cells per rat. Intraperitoneal administration of dioxadet as well as chemoperfusion was performed once in 48 hours after the ovarian cancer inoculation. Dioxadet was used at maximal tolerated doses which were 1.5 mg/kg for intraperitoneal administration, 30 mg/kg for normothermic intraperitoneal chemoperfusion (IPEC), and 15 mg/kg for hyperthermic intraperitoneal chemoperfusion (HIPEC). Antitumor effects of dioxadet were estimated in increase of median survival. In the control group, where animals didn't receive any treatment, the median survival was 9 days. Increase of the median survival after intraperitoneal administration of dioxadet, IPEC and HIPEC with dioxadet was 211% (p=0,001), 244% (p=0,001) and 444% (p=0,001), respectively, compared to the control group. Hence, intraperitoneal chemoperfusion with dioxadet (normo- or hyperthermic) is more effective compared to standard intraperitoneal administration of the drug. At HIPEC with dioxadet potentiating antitumor action of hyperthermia and dioxadet on the ovarian cancer growth was achieved.
authors.forename: V G
authors.initials: VG
authors.lastname: Bespalov
authors.forename: O A
authors.initials: OA
authors.lastname: Beliaeva
authors.forename: G S
authors.initials: GS
authors.lastname: Kireeva
authors.forename: K Iu
authors.initials: KIu
authors.lastname: Senchik
authors.forename: A N
authors.initials: AN
authors.lastname: Stukov
authors.forename: V A
authors.initials: VA
authors.lastname: Aristova
authors.forename: E A
authors.initials: EA
authors.lastname: Vyshinskaia
authors.forename: S A
authors.initials: SA
authors.lastname: Kon'kov
authors.forename: I A
authors.initials: IA
authors.lastname: Krylova
authors.forename: A L
authors.initials: AL
authors.lastname: Semënov
authors.forename: M A
authors.initials: MA
authors.lastname: Maĭdin
authors.forename: V A
authors.initials: VA
authors.lastname: Aleksandrov
authors.forename: A M
authors.initials: AM
authors.lastname: Beliaev
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology*; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods; D005260:Female; D006979:Hyperthermia, Induced; D007263:Infusions, Parenteral; D009374:Neoplasms, Experimental / Q000188:drug therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D016019:Survival Analysis; D016896:Treatment Outcome; D014227:Triazines / Q000008:administration & dosage* / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D014227:Triazines; C040269:dioxadet